

US Family Health Plan Prior Authorization Request Form for ixekizumab (**Taltz**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? **Call 1-877-880-7007**

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete the clinical assessment:

<p>1. What is the patient's age?</p>	<input type="checkbox"/> 18 years of age or older – proceed to question 2 <input type="checkbox"/> 6 years of age to less than 18 years of age proceed to question 3 <input type="checkbox"/> Younger than 6 years of age – STOP Coverage not approved	
<p>2. What is the indication or diagnosis in this adult patient?</p>	<input type="checkbox"/> Active psoriatic arthritis – Proceed to question 4 <input type="checkbox"/> Moderate to severe plaque psoriasis in a patient who is a candidate for systemic therapy or phototherapy. – Proceed to question 4 <input type="checkbox"/> Active ankylosing spondylitis (AS) – Proceed to question 4 <input type="checkbox"/> Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation AND evidence of elevated CRP and/or MRI evidence of sacroiliitis and ASDAS greater or equal to 2.1 – Proceed to question 4 <input type="checkbox"/> Other indication or diagnosis – STOP Coverage not approved.	
<p>3. What is the indication or diagnosis in this pediatric patient?</p>	<input type="checkbox"/> Moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy– Proceed to question 10 <input type="checkbox"/> Other indication or diagnosis – STOP Coverage not approved.	
<p>4. Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?</p>	<input type="checkbox"/> Yes proceed to question 5	<input type="checkbox"/> No proceed to question 7
<p>5. Has the patient had an inadequate response to Humira?</p>	<input type="checkbox"/> Yes proceed to question 8	<input type="checkbox"/> No proceed to question 6
<p>6. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?</p>	<input type="checkbox"/> Yes proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved

USFHP Prior Authorization Request Form for
ixekizumab (**Taltz**)

<p>7. Does the patient have a contraindication to Humira (adalimumab)?</p>	<p><input type="checkbox"/> Yes proceed to question 8</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>8. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Cosentyx (secukinumab)?</p>	<p><input type="checkbox"/> Yes proceed to question 9</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>9. Is the requested medication being used for:</p> <ul style="list-style-type: none"> • ankylosing spondylitis (AS) or • non-radiographic axial spondyloarthritis (nr-axSpA) 	<p><input type="checkbox"/> Yes proceed to question 11</p>	<p><input type="checkbox"/> No proceed to question 10</p>
<p>10. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a contraindication to Stelara (ustekinumab)?</p>	<p><input type="checkbox"/> Yes proceed to question 11</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>11. Has the patient had an inadequate response to non- biologic systemic therapy? (For example: methotrexate, aminosaliclates [e.g. sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g. azathioprine], etc.)</p>	<p><input type="checkbox"/> Yes proceed to question 12</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>12. Does the patient have evidence of a negative TB test result in the past 12 months (or TB is adequately managed)?</p>	<p><input type="checkbox"/> Yes proceed to question 13</p>	<p><input type="checkbox"/> No STOP Coverage not approved</p>
<p>13. Will the patient be receiving other targeted immunomodulatory biologics with the requested medication including but not limited to the following: Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orenzia, Otezla, Remicade, Rinvoq ER, Rituxan, Siliq, Simponi, Skyrizi, Stelara, Tremfya or Xeljanz/Xeljanz XR?</p>	<p><input type="checkbox"/> Yes STOP Coverage not approved</p>	<p><input type="checkbox"/> No Sign and date below</p>

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date

[30 December 2020]